Tcrx Therapeutics Co.ltd
Clinical trials sponsored by Tcrx Therapeutics Co.ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Custom immune attack: new gene therapy targets Hard-to-Treat cancers Results expected Dec 2026 (estimated)
- New gene therapy trial hopes to tame advanced cancers Results expected Dec 2026 (estimated)
-
New gene therapy targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new treatment called KXV01 for people with advanced solid tumors, including sarcomas, who have no other options. The therapy uses a patient's own immune cells, modified with a virus to recognize and attack their specific tumor. The main goal is…
Phase 1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New injection shows promise for tough lymphoma cases
Disease control Recruiting nowThis early-phase study tests a new drug called KSV01 in 18 adults with relapsed or refractory diffuse large B-cell lymphoma, a type of blood cancer that has not responded to standard treatments. The main goal is to check the safety of the injection and find the best dose. Partici…
Phase 1 • Sponsor: TCRx Therapeutics Co.Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Healthy donors needed to supply immune cells for future drug research
Knowledge-focused Recruiting nowThis study collects peripheral blood mononuclear cells (immune cells) from 200 healthy volunteers aged 18 to 40 using a process called apheresis. The cells will be used in the lab to study how they grow and function, helping researchers develop new drugs. No treatment or medicati…
Sponsor: TCRx Therapeutics Co.Ltd • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC